Reply to: Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide

Andrew J. Armstrong

Arun A. Azad

Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

Fred Saad

Centre Hospitalier de l’Université de Montréal, University of Montreal, Montreal

Maha Hussain

Taro Iguchi

Andrew J. Armstrong, MD, ScM, FACP, Division of Medical Oncology, Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC; Arun A. Azad, MBBS, PhD; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia; Fred Saad, MD, University of Montreal Hospital Center, Montreal, QC, Canada; Maha Hussain, MD, FACP, FASCO, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; Taro Iguchi, MD, PhD, Department of Urology, Kanazawa Medical University, Ishikawa, Japan; Arnulf Stenzl, MD, Department of Urology, University of Tübingen, Tübingen, Germany; and Cora N. Sternberg, MD, FACP, Englander Institute for Precision Medicine, Meyer Cancer Center, Weill Cornell Medicine, New York, NY

Arnulf Stenzl

Andrew J. Armstrong, MD, ScM, FACP, Division of Medical Oncology, Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC; Arun A. Azad, MBBS, PhD; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia; Fred Saad, MD, University of Montreal Hospital Center, Montreal, QC, Canada; Maha Hussain, MD, FACP, FASCO, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; Taro Iguchi, MD, PhD, Department of Urology, Kanazawa Medical University, Ishikawa, Japan; Arnulf Stenzl, MD, Department of Urology, University of Tübingen, Tübingen, Germany; and Cora N. Sternberg, MD, FACP, Englander Institute for Precision Medicine, Meyer Cancer Center, Weill Cornell Medicine, New York, NY

Cora N. Sternberg

Andrew J. Armstrong, MD, ScM, FACP, Division of Medical Oncology, Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC; Arun A. Azad, MBBS, PhD; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia; Fred Saad, MD, University of Montreal Hospital Center, Montreal, QC, Canada; Maha Hussain, MD, FACP, FASCO, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; Taro Iguchi, MD, PhD, Department of Urology, Kanazawa Medical University, Ishikawa, Japan; Arnulf Stenzl, MD, Department of Urology, University of Tübingen, Tübingen, Germany; and Cora N. Sternberg, MD, FACP, Englander Institute for Precision Medicine, Meyer Cancer Center, Weill Cornell Medicine, New York, NY